Management of arrythmia in the COVID 19 era

Article Sidebar

PDF
Published: Dec 14, 2021
DOI: https://doi.org/10.47577/biochemmed.v2i4.5358
Keywords:
COVID 19, Arrhythmias, Severe acute respiratory syndrome, Viral infection

Main Article Content

Sirma Tomos
Faculty of Pharmacy, Ovidius University of Constanta, Romania
Verginica Schroder
Faculty of Pharmacy, Ovidius University of Constanta, Romania
Doina Margaritti
Faculty of Pharmacy, Ovidius University of Constanta, Romania
Florica Busuricu
Faculty of Pharmacy, Ovidius University of Constanta, Romania

Abstract

There is currently well-documented evidence that SARS CoV2 infection is frequently associated with secondary cardiac damage. Although lung damage is a priority, the evolution over time of COVID 19 infection frequently includes cardiovascular complications, the most common being: myocarditis, heart failure and acute coronary syndrome resulting from coronary artery thrombosis or plaque ruptures associated with SARS-CoV-2. Therefore, for the judicious use of resources, both human and material, and for the protection of medical staff, it is necessary to establish standard procedures to limit the contact of medical staff with the infected patient COVID 19.
img1.jpg

Article Details

How to Cite
Tomos, S., Schroder, V., Margaritti, D., & Busuricu, F. (2021). Management of arrythmia in the COVID 19 era . Technium BioChemMed, 2(4), 106–111. https://doi.org/10.47577/biochemmed.v2i4.5358
Issue
Vol. 2 No. 4 (2021): Technium BioChemMed
Section
Articles

References

COVID-19 Map. In: Johns Hopkins Coronavirus Resource Center. Available: https://coronavirus.jhu.edu/map.html. Accessed 26.November 2021

S. BABAPOOR-FARROKHRAN, D. GILL, J. WALKER, R.T. RASEKHI, B. BOZORGNIA, A. AMANULLAH: Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020; 253 :117723. doi: 10.1016/j.lfs.2020.117723.

K. LIU, Y.Y. FANG, Y. DENG, W. LIU, M.F.WANG, J.P. MA, W. XIAO, Y.N. WANG, M.H. ZHONG, CH. LI, GC. LI, HG. LIU: Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020; 133 (9):1025–1031. doi:10.1097/CM9.0000000000000744

D. WANG, B. HU, C. HU, F. ZHU, X. LIU, J. ZHANG, B. WANG, H. XIANG, Z. CHENG, Y. XIONG, Y. ZHAO, Y. LI, X. WANG, Z. PENG:Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585

G. TSE, J.M. YEO, Y.W. CHAN, LAI ETHL, B.P. YAN: What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies Front Physiol. 2016; 7 :308. doi: 10.3389/fphys.2016.00308.

L. K. ALEXANDER, B. W. KEENE, J. D. SMALL, B. YOUNT, R. S. BARIC. Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy. Adv Exp Med Biol.1993;342:365–370. doi:10.1007/978-1-4615-2996-5_56.

P. P. LIU, J.W. MASON: Advances in the understanding of myocarditis. Circulation. 2001;104 (9):1076–1082. doi: 10.1161/hc3401.095198

A. J. BAKSI, G. S. KANAGANAYAGAM, S. K. PRASAD: Arrhythmias in viral myocarditis and pericarditis. Card Electrophysiol Clin. 2015;7(2):269–281. doi:10.1016/j.ccep.2015.03.009 - 10.1007/s10840-020-00789-9

Z. LI, W. SHAO, J. ZHANG, J. MA, S. HUANG, P. YU, W. ZHU, X. LIU: Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021;8:720129. Epub 2021 Oct 13; https://doi.org/10.3389/fcvm.2021.720129

S. E. MOUNTANTONAKIS, M. SALEH, J. FISHBEIN, A. GANDOMI, M. LESSER, J. CHELICO, J. GABRIELS, M. QIU, L. M. EPSTEIN: Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Northwell COVID-19 Research Consortium Heart Rhythm. 2021;18(4):501-507; doi: 10.1016/j.hrthm.2021.01.018. Epub 2021 Jan 22.

T. GUO, Y. FAN, M. CHEN, X. WU, L. ZHANG, T. HE, H. WANG, J. WAN, X. WANG, Z. LU:Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) - JAMA Cardiol. 2020;5(7):811-818; DOI: 10.1001/jamacardio.2020.1017

S. RICHARDSON, J. S. HIRSCH, M. NARASIMHAN, J. M. CRAWFORD, T. MCGINN, K. W. DAVIDSON et. al.:The Northwell COVID-19 Reasearch Consortium: Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059; https://doi.org/10.1001/jama.2020.6775

E. CHORIN, M. DAI, E. SHULMAN, A. L. ET:The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020; 26, 808-809; https://doi.org/10.1038/s41591-020-0888-2

A. MAZZANTI, M. BRIANI, D. KUKAVICA, F. BULIAN:Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. Circulation. 2020;142(5):513. https://doi.org/10.1161/CIRCULATIONAHA.120.048476

O. VOISIN, E. L. LORC'H, MAHÉA: Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. Mayo Clin Proc. 2020;95 (8):1696. https://dx.doi.org/10.1016%2Fj.mayocp.2020.05.005

C. I. WU, P. G. POSTEMA, E. ARBELO, E. R. BEHR: SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm. 2020;17(9):1456. https://doi.org/10.1016/j.hrthm.2020.03.024

J. E. TISDALE, H. A. JAYNES, J. R. KINGERY, N. A. MOURAD: Development and validation of a risk score to predict QT interval prolongation in hospitalized pacients - Cardiovasc Qual Outcomes. 2013;6 (4):479. https://doi.org/10.1161/CIRCOUTCOMES.113.000152

https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19

Most read articles by the same author(s)

1 2 > >> 

Similar Articles

<< < 1 2 3 4 > >> 

You may also start an advanced similarity search for this article.